02 apr: Kapitalforeningen World Wide Invest – navneændring til Kapitalfor..
02 apr: Investeringsforeningen Multi Manager Invest - forløb af ordinær g..
02-04-2019 14:58:36

Genmab to Present at the H.C. Wainwright & Co. Global Life Sciences Conference

Media Release

Copenhagen, Denmark, April 2, 2019

Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the H.C. Wainwright & Co. Global Life Sciences Conference in London at 11:30 AM BST on April 9, 2019 (12:30 PM CEST). A webcast of the presentation will be available on Genmab’s website at https://ir.genmab.com/events.cfm.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Media Release no. 04

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
17 apr - 
Aktier/tendens: Panalpina-tal kan give DSV-fokus i roli..
16 apr - 
Tirsdagens aktier: Lidt skuffende Darzalex-salgstal sen..
16 apr - 
Genmab/Sydbank: Darzalex-skuffelse skyldes især salg ud..
Relateret debat
17 apr - 
Shortene har måske en større strategi som vi ikke kende..
17 apr - 
Jeg tror da, shorterne regner med at forventningerne in..
16 apr - 
Helt enig i dine betragtninger lerner. Genmab er lavt p..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Euroinvestor spørger: Hvor ser du Apples aktiekurs om 12 måneder?

24-04-2019 10:51:00
Hvor ser du Apples aktiekurs om 12 måneder? Det er ét af de spørgsmål, vi stiller i vores Privatinvestorundersøgelse (PIU) i april.Vi spørger også om dine forventninger til aktiemarkederne, boligmarkedet og økonomien. Hos Euroinvestor mener vi nemlig, at den bedste kilde til viden om markedet er aktørerne i markedet. 

Finanskommentaren: Trumps Iran-trusler sender olieprisen i vejret

Relaterede nyheder
24-04-2019 07:00:00
Af Jens Nærvig Pedersen, seniorstrateg, Danske Bank I slutningen af marts proklamerede USA’s præsident Donald Trump på Twitter, at olieprisen var ved at blive for høj. På det tidspunkt lå prisen på en tønde olie omkring 67 dollar, men henover påsken nåede den op over 74 dollar – det højeste siden begyndelsen af november sidste år. Paradoksalt nok har USA til trods for præsidentens bekymringer selv..

Snap Inc. løftes af regnskab

Relaterede nyheder
24-04-2019 06:33:44
Det amerikanske sociale medie og beskedservice Snap var bedre på både top og bund i første kvartal end ventet, og samtidig steg antallet af daglige brugere mere end ventet.Det fremgår af regnskabet for kvartalet, som er blevet offentliggjort efter markedets lukning tirsdag. I eftermarkedet hoppede aktien op med helt op til 14 pct., men efterfølgende vendte den rundt og gik kortvarigt i minus, inde..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
NKT mistede halv milliard på børsen: Frygt for misset kontrakt
2
Hedgefond skruer ned Zealand Pharma-short
3
Tirsdagens aktier: NKT ned på ventet misset ordre - Pandora i nyt fald
4
Aktier/tendens: Novozymes' skuffende regnskab løber med opmærksomheden
5
Novozymes nedjusterer efter skuffende skuffende regnskab – aktien dykker

Relaterede aktiekurser

Genmab A/S 1.117,00 -0,6% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. april 2019 16:07:18
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190410.2 - EUROWEB3 - 2019-04-24 16:07:18 - 2019-04-24 16:07:18 - 1 - Website: OKAY